Compound 11 may be competitive against both substrate and NAD+; 11 and 12 can significantly reverse the cytotoxicity induced by α-synuclein aggregation in SH-SY5Y cells, which laid the foundation for the research of SIRT2 inhibitors for potential therapy against Parkinson's disease.35 This evidence concerns the gene SIRT2 and Parkinson disease.